Bio-Rad Laboratories, Inc. filings document operating results, governance, capital structure, and material events for a Delaware company that develops, manufactures, and markets life science research and clinical diagnostics products.
Form 8-K reports furnish quarterly and annual earnings releases, supplemental earnings materials, Regulation FD presentations, Droplet Digital PCR product-portfolio disclosures, and updates related to the company’s investment in Sartorius AG. Proxy materials cover board elections, executive compensation, shareholder voting matters, governance practices, and Class A and Class B common stock disclosures.
Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported changes in his beneficial ownership on September 1, 2025. He acquired 6,353 Class A shares on vesting of restricted stock units and had 3,084 Class A shares disposed of at $297.88 per share. After these transactions he directly owned 441,507 Class A shares. The filing also reports direct ownership of 361,466 Class B shares and indirect holdings of 13,006 Class B shares (by spouse) and 4,060,054 Class B shares (by Blue Raven Partners, L.P.). Several restricted stock unit vesting events are noted, reflecting prior grants from 2021–2023 that vest in annual installments.
Bio-Rad Laboratories, Inc. filed a report describing an informational investor webinar focused on its Droplet Digital™ PCR (ddPCR™) product portfolio held on August 26, 2025. The webinar included a presentation and Q&A session with President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. A live webcast and a replay, along with the slide presentation, are or will be available for up to a year in the Investor Relations section of the company’s website under “Events & Presentations.” The slide deck for the webinar is also provided as Exhibit 99.1, with the disclosure treated as furnished under Regulation FD rather than filed for liability purposes.
Rajat Mehta, listed as Executive Vice President, GBL Commercial Operations at Bio-Rad Laboratories (BIO), filed an initial Form 3 reporting the Section 16 beneficial-ownership status. The event date is 08/04/2025 and the form is signed 08/14/2025. The filing states no securities beneficially owned (0 shares) by the reporting person, with ownership shown as direct (D) where applicable.